Delivery Order 75N95022D00013-75N95022F00002
Award Date 9/22/22
Potential Completion Date 9/21/25
Potential Value $116K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Labor Hours
Place of Performance
San Jose, CA 95131, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
3
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- CCS Associates, Inc. has been awarded a delivery order against their indefinite delivery/indefinite quantity contract by the Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences. The $242,354.81 order is for the preparation of an Investigational New Drug application to the Food and Drug Administration for a treatment for Jansen's Metaphyseal Chondrodysplasia. Work will be performed in San Jose, California through June 9,...
- This is a delivery order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to CCS Associates, Inc., a woman-owned small business. The $545,690.33 contract is for regulatory activities supporting PCCA and MMAB gene therapy products. The contract has a period of performance through May 20, 2028 and is a labor hours contract type. CCS Associates has previously secured several large Indefinite Delivery Vehicle (IDV) contracts with NCATS, the...
- This is a one-year, $113,077 cost-plus-fixed-fee delivery order awarded by the National Institutes of Health (NIH)'s National Institute on Drug Abuse to CCS Associates, Inc., a woman-owned small business, for regulatory affairs support. The order is part of a larger indefinite delivery vehicle (IDV) that CCS Associates holds from NIH to provide regulatory affairs assistance through 2028. CCS Associates has extensive experience supporting pharmaceutical research, clinical trials, regulatory...
- CCS Associates, Inc. was awarded a $461,849 purchase order by the Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse to provide medical writing consulting and drug dossier development support services. The contract calls for the contractor to prepare regulatory documents and drug dossiers to support the Blueprint Neurotherapeutics Program, Early Phase Pain Investigation Clinical Network, and other NIH neuroscience research initiatives. Awarded...
- This is a delivery order contract awarded to CCS Associates, Inc., a woman-owned small business, by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The $3,882,241.70 firm fixed price contract provides administrative support services to the NCI. CCS Associates has secured numerous federal contracts and grants to assist government agencies in advancing medical research and drug development...
- CCS Associates, Inc. was awarded a $419,664 purchase order contract by the Department of Health and Human Services' National Institutes of Health National Institute of Neurological Disorders and Stroke to provide regulatory affairs consulting support services. The contract has a period of performance from September 2020 through September 2023. It is designated as a total small business set aside and will be performed by CCS Associates in San Jose, California. The National Institute of...
- This is a Definitive Contract awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to CCS Associates, Inc., a woman-owned small business. The contract, valued at $106,370.26, is for regulatory affairs consulting support services related to the Brain Program Network (BPN) initiative. The contract was awarded as a Total Small Business set-aside on September 4, 2015 and is scheduled for completion on September 13, 2020. CCS Associates has...
- This $548,714.60 firm fixed-price delivery order contract was awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. Department of Health and Human Services, to CCS Associates, Inc., a woman-owned small business. The contract is for TAS (Task Area Support) to provide strategic planning and activities support for NCI's Center for Strategic Scientific Initiatives (CSSI). CCS Associates specializes in providing comprehensive research support services to federal agencies,...
- This $1,286,665.09 federal contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to CCS Associates, Inc., a woman-owned small business contract research organization. The contract is a delivery order and has a firm fixed price pricing type. CCS Associates will provide a range of services to support NCI's cancer prevention efforts, including information management, regulatory services, and technical support. The contract is not a set-aside...
- The National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), awarded a $375,748 purchase order for medical writing consulting services to CCS Associates, Inc., a woman-owned small business based in San Jose, California. The services will support various neuroscience drug development programs, including the Blueprint Neurotherapeutics Program, the NIH Helping to End Addiction Long-term (HEAL) Initiative, and the Early Phase Pain Investigation...
- 75N95022D00013Indefinite Delivery Contract
- 75N95022D00013-75N95022F00002Delivery Order
CCS Associates, Inc. was awarded a delivery order against an unspecified contract vehicle to provide regulatory support services to the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH). The $115,581.31 contract calls for CCS Associates to prepare and file a Pre-Investigational New Drug (Pre-IND) application with the Food and Drug Administration (FDA) to support the clinical development of mitragynine. No set-aside designation was applied. Performance will occur in San Jose, California through September 2025. NCATS works to transform the translational science process to get new treatments to patients faster via pre-clinical and clinical collaborations.
Generated 1/3/24, 5:20 PM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Exercise an Option | $1.6k | 10/27/23 | |
| P00001 | Supplemental Agreement for work within scope | $0 | 8/15/23 | |
| Not listed | Not listed | $109.5k | 9/19/22 |